Hypertension, obesity and their medications in relation to renal cell carcinoma. by Yuan, J. M. et al.
British Joumal ofCancer(1998) 77(9), 1508-1513
© 1998 Cancer Research Campaign
Hypertension, obesity and their medications in relation
to renal cell carcinoma
J-M Yuan, JE Castelao, M Gago-Dominguez, RK Ross and MC Yu
Department of Preventive Medicine, USC/Norris Comprehensive Cancer Center, University of Southern California, Los Angeles, CA 90033-0800, USA
Summary A population-based, case-control study was conducted in Los Angeles County, California, to investigate the inter-relationships of
obesity, hypertension and medications in relation to renal cell carcinoma (RCC) risk. A total of 1204 RCC patients and an equal number of
neighbourhood controls were included. Obesity was a strong risk factor for RCC. A fourfold increase in risk was observed forthose with usual
body mass index (kg m-2) of . 30 vs <22. A history of hypertension was another strong, independent risk factor for RCC [odds ratio
(OR) = 2.2; 95% confidence interval (Cl) = 1.8, 2.6]. There was little evidence that use of diuretics was directly related to RCC development.
Use of diuretics for reasons other than hypertension (primarily for weight control) was unrelated to risk among self-reported normotensive
subjects (OR = 1.2; 95% Cl = 0.7, 2.2). Among hypertensive subjects, heavy users of diuretics experienced similar risk as light users
(OR = 0.9 among subjects with lifetime dose of . 137 g compared with those with lifetime dose of < 43g). Similarly, normotensive subjects
who took non-diuretic antihypertensives regularly showed no increased risk for RCC (OR = 1.1; 95% Cl = 0.6-1.8), and intake among
hypertensive subjects did not further increase their risk. Regular use of amphetamine-containing diet pills was associated with a twofold
increase in RCC risk (95% Cl = 1.4-2.8) and the risk increased with increasing dose of amphetamines. However, the fraction of cases
possibly related to this exposure is small (population-attributable risk = 5%).
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In 1986, we reported that use of diuretics and diet pills might be
related to risk ofrenal cell carcinoma (RCC) (Yu et al, 1986). The
two common indications for use of diuretics and diet pills
(i.e. hypertension and obesity) were also positively related to RCC
in that study. The association between hypertension and RCC in
women was attenuated after adjustment for diuretic use, whereas
the latter remained a strong risk factor for RCC after adjustment
for history of hypertension. However, the crude assessment of
medication history raised concern regarding the validity of those
findings. History of diuretic use was assessed through a single
question, 'Have you ever taken diuretics for 6 weeks or longer,
either continuously or during any one year?' and use of diet pills
was abstracted from response to the open-ended question, 'Have
you ever taken any other medications for 6 weeks or longer, either
continuously or during any one year?'
Given that diuretics and certain types of diet pills are known to
have biological actions on the renal epithelium and that the former,
in particular, is an extremely heavily prescribed medication, it is
important to establish if use of diuretics and/or diet pills, and the
conditions (hypertension and/or obesity) that call for their use, are
independently related to risk of RCC. We report here a
case-control study that was designed specifically to investigate the
inter-relationships ofthese factors and RCC risk.
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MATERIALS AND METHODS
The Los Angeles County Cancer Surveillance Program (Bern-
stein and Ross, 1991), the population-based Surveillance,
Epidemiology and End Results (SEER) cancer registry of Los
Angeles County, identified 1724 non-Asian patients aged 25-74
years with RCC histologically diagnosed between April 1986 and
December 1994. Of these, 301 patients died before we could
contact them or were too ill to be interviewed. Permission to
contact 56 patients was denied by attending physicians. Ninety-
one patients refused to be interviewed. Thus, we interviewed 74%
(1276 out of 1724) of all eligible patients.
For each recruited patient, we sought to interview a control who
was matched to the case for sex, date of birth (within 5 years),
race, and neighbourhood of residence at the time of cancer diag-
nosis. We attempted to identify the sex, age and race ofall inhabi-
tants of each housing unit on specified neighbourhood blocks.
When we failed to find any eligible resident after canvassing 150
housing units, we then dropped race as a matching criteria. If a
matched control could still not be found within a maximum of300
housing units, the case was dropped from the study. Seventy-two
cases were excluded because of lack of matched controls. We
completed interviews on 1204 control subjects and, of these, 98
were not matched by race to the index case. Our goal was to inter-
view the first resident in the 'walk' sequence who met our
matching criteria. Eight-hundred and thirty-four (69%) control
subjects were first eligible residents, whereas 231 (19%) and 139
(12%) were second and third eligible residents respectively.
In-person, structured interviews were conducted in subjects'
homes. The questionnaire requested information up to 2 years
before the diagnosis of cancer for cases and 2 years before diag-
nosis of cancer of the index case for matched controls. Questions
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Table 1 The effect of obesity on risk of renal cell carcinoma
Usual body mass Total Men Women
index (kg m-2) Cases Controls ORB (95% Cl) Cases Controls OR" (95% Cl) Cases Controls OR" (95%Cl)
<22 188 289 1.0 62 112 1.0 126 177 1.0
22-<24 247 269 1.6 (1.3-2.2) 152 179 1.7 (1.1-2.5) 95 90 1.7 (1.1-2.5)
24-<26 266 294 1.5 (1.2-2.0) 200 229 1.6 (1.1-2.4) 66 65 1.5 (0.96-2.3)
26-<28 164 170 1.7 (1.3-2.4) 129 128 2.0 (1.3-3.1) 35 42 1.3 (0.7-2.2)
28-<30 139 96 2.5 (1.8-3.5) 107 76 2.7 (1.7-4.3) 32 20 2.3 (1.2-4.2)
.30 200 86 4.3 (3.0-6.1) 131 57 4.6 (2.9-7.5) 69 29 4.0 (2.3-7.0)
aOR, odds ratio, adjusted for level of education (high school or less, college orabove); Cl, confidence interval.
included: demographic characteristics, adult height, weight at age
20, usual adult weight, maximum adult weight that was unrelated
to pregnancy, lifetime use of tobacco and alcohol, usual dietary
habits, lifetime occupational history, history of physician-diag-
nosed hypertension and other selected medical conditions, use of
diuretics and other commonly prescribed drugs to control hyper-
tension, use ofprescription and non-prescription diet pills, and use
ofprescription andnon-prescription analgesics. We listed 58 brand
names of diuretics and antihypertensives, and 26 diet pills in the
questionnaire (see Appendix), drugs representing all the common
prescription medications in these respective categories marketed
in the United States since the 1950s. Apicture album ofthe named
drugs was available to the respondent to assist in recall.
Regular use was defined as taking a listed brand name drug two
or more times a week for 1 month or longer. We asked subjects the
ages at first and last use, duration of use, usual dosage, and the
primary reason for such use, including any other brand name
diuretics, antihypertensives, or diet pills that were not listed in the
questionnaire.
We attempted to verify self-reported usage of all prescription
diuretics, antihypertensives and diet pills. All physicians named
by study subjects were contacted to request information on dates
of continuous care of the patients and details on the named
prescriptions.
The formulations of each of the listed drugs as well as those
volunteered by study subjects were established through numerous
pharmaceutical sources, including the annually updated
Physician's Desk Reference. Each class of drugs was then placed
into major formulation categories; for example, diuretics were
grouped as thiazides, furosemides or potassium-sparing diuretics.
Antihypertensives were classified as beta blockers, central anti-
adrenergic agents, neuronal depleting agents, angiotensin-
converting enzyme inhibitors or vasodilators. Diet pills were
categorized as amphetamines or other anorexic drugs. Age-
specific exposure to a given drug was estimated from the subject's
reported dose and duration ofuse at that age. Lifetime cumulative
exposure to a specific class of compounds (in grams) was
computed by summing age-specific exposures across all brand
name drugs belonging to that class of compounds. Cumulative
exposures were grouped into tertiles according to their distribu-
tions among control subjects.
Data were analysed using standard matched-pair methods
(Breslow and Day, 1980). The associations of RCC with the
various exposures were measured by odds ratios (ORs) and their
corresponding 95% confidence intervals (CIs). Conditional
logistic regression models were used to examine the univariate and
multivariate relationships ofRCC with various exposure variables,
and to adjust for potential confounding factors including regular
use of analgesics (M Gago-Dominguez et al, submitted for pub-
lication) and cigarette smoking (JM Yuan et al, submitted for
publication), which were significant risk factors for RCC iden-
tified in the present study. The analysis of covariance methods
(Winer, 1971) were used to compare levels of cumulative dosage
of diuretics between cases and controls stratified by history of
hypertension while controlling for age, level of education and
obesity. ORs with two-sided P-values less than 0.05 are considered
statistically significant. All P-values quoted are two-sided.
RESULTS
There were 781 male and 423 female patients. The mean age at
diagnosis of RCC was 58.8 years. Among patients, 1028 were
non-Hispanic whites, 107 were Hispanic whites and 69 were
blacks. Since 48% of cases vs 37% of control subjects did not
attend college (OR = 0.6; 95% CI = 0.5-0.7), all subsequent
analyses were adjusted for level ofeducation.
The body mass index (BMI, defined as weight in kg divided by
height in m squared, kg m-2) was used as a marker of obesity. All
three BMIs studied (i.e. BMI at age 20, maximum BMI and usual
BMI) were significantly associated with riskofRCC and strengths
of their associations were broadly similar. Results were also
similar between men and women (Table 1).
A history ofhypertension was significantly related to a 2.2-fold
excess in RCC risk. Because advanced renal disease can lead to
hypertension, we examined risk according to time interval
between two diagnoses. There was little variation in risk between
the subgroups. There was also no statistical difference in risk
for RCC between treated and untreated hypertensive patients
(P = 0.11) (Table 2).
In univariate analysis, significantly increased risks for RCC
were noted among diabetics (OR = 1.6; 95% CI = 1.1-2.2) and
stroke patients (OR = 2.1; 95% CI = 1.2-3.7). However, after
adjustment for level ofeducation, usual BMI and history ofhyper-
tension, the ORs reduced to 0.9 for diabetes and 1.2 for stroke,
neither of which was statistically significant. No statistically
significant association with RCC was observed for prior renal
conditions such as renal stones, renal injury, renal infection or
other renal disorders (data not shown).
Table 3 presents the combined effect of obesity and hyperten-
sion on risk of RCC. Regardless of hypertension status, the ORs
increased with increasing usual BMI. Similarly, irrespective of
level of usual BMI, hypertensive subjects had a roughly twofold
increase in risk of RCC relative to normotensive subjects. Further
adjustment for cigarette smoking, regular use of analgesics and
regular use of amphetamines (see below) had little effect on the
association.
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Table 2 The effect of hypertension on risk of renal cell carcinoma
Hypertension Cases Controls ORa (95% Cl)
No 669 875 1.0
Yesb 535 329 2.2 (1.8-2.6)
Number of years since first diagnosis
<5 55 40 2.1 (1.3-3.2)
5-9 122 85 1.8 (1.4-2.5)
10-19 188 96 2.6 (2.0-3.4)
20-29 97 62 2.2 (1.6-3.2)
.30 63 40 2.0 (1.3-3.1)
Unknown 10 6 1.8 (0.7-5.2)
Ever medically treated (by diuretics or antihypertensive drugs)
No 98 74 1.7 (1.2-2.3)
Yes 437 255 2.3 (1.9-2.9)
aOR, odds ratio, adjusted for level of education (high school or less, college or above); Cl, confidence interval. bDiagnosed by
physician.
Table 3 The combined effect of obesity and hypertension on risk of renal cell carcinoma
Usual body mass No hypertension Hypertension
index (kg m-2) Cases Controls OR' (95% Cl) Cases Controls OR' (95% Cl)
<22 135 236 1.0 53 53 1.8 (1.1-2.8)
22-<24 157 211 1.5 (1.1-2.1) 90 58 3.4 (2.2-5.2)
24-<26 165 212 1.5 (1.1-2.1) 101 82 2.3 (1.6-3.4)
26-<28 72 104 1.5 (0.98-2.2) 92 66 2.8 (1.9-4.3)
28-<30 60 63 1.8 (1.2-2.9) 79 33 4.6 (2.9-7.5)
.30 80 49 3.2 (2.0-5.2) 120 37 7.0 (4.4-11.3)
aOR, odds ratio, adjusted for level of education (high school or less, college or above); Cl, confidence interval.
Irregular use of diuretics was unrelated to risk for RCC (OR =
1.3; 95% CI = 0.7, 2.5 relative to never users), whereas regular
users exhibited a 2.2-fold increased risk (95% CI = 1.8, 2.8). We
examined the relationship between regular use of diuretics and
RCC development by hypertensive status (Table 4). All hyperten-
sive users indicated that the reason for taking diuretics was for
hypertension control. Among the self-reported normotensive
users, fluid/weight loss was the primary reason forusing the 'water
pill' (21 cases, 19 controls). The other main reason was for heart
problems (four cases, three controls). Among normotensive
subjects, there was no significant association between diuretic use
and RCC risk. Furthermore, mean cumulative lifetime dose of
diuretics in normotensive cases was similar to thatin normotensive
controls. Similarly, among hypertensive subjects, risk was unre-
lated to cumulative lifetime dose ofdiuretics. Results were similar
when we repeated the analysis within subgroups of diuretics
according to formulation [see Table 4 for thiazides and potassium-
spacing diuretics; data for furosemides not shown, being based on
smaller numbers (73 cases, 31 controls)].
Twenty-one cases and four controls had used spironolactone
regularly, and all except one control reported a history ofhyperten-
sion. Although the OR was relatively high forthis agent (OR = 3.5;
95% CI = 1.1-10.8), there was no statistical difference in the risk of
RCC between users of spironolactone and users of other diuretics,
after adjustment for level ofeducation and usual BMI (P = 0.26).
We also examined the association between non-diuretic medica-
tions used for hypertension control and RCC. Relative to non-
users, no increased risk of RCC was observed among irregular
users (OR = 1.0), whereas regular use was associated with a 1.8-
fold increase in risk (95% CI = 1.4-2.2). Among self-reported
normotensive subjects, 33 cases and 37 controls had used anti-
hypertensives regularly (OR = 1.1; 95% CI =0.6-1.8). Theprimary
reasons for such use were heart problems (22 cases, 27 controls)
and migraine headaches (six cases, four controls). Among hyper-
tensive subjects, there was no significant difference in cumulative
lifetime dose (in grams) of antihypertensives between cases and
controls (P = 0.13). The results of analyses by subgroup of anti-
hypertensives (betablockers, central antiadrenergic agents, neuronal
depleting agents, angiotensin-converting enzyme inhibitors, and
vasodilators) were consistent with those based on the full data set.
A statistically significant 60% increased risk ofRCC was noted
in those who useddietpills regularly compared with those who did
not. The effect was confined to subjects who used amphetamine-
containing diet pills. We examined the association between RCC
risk and amphetamines by dose level and by reason for use. There
was a monotonic increase in risk by increasing maximum weekly
dose of amphetamines (P < 0.001, linear trend test) after adjust-
ment for level of education, usual BMI and history of hyperten-
sion. Reason for use of amphetamines had no influence on risk
level (Table 5).
The multivariate relationship of RCC with usual BMI, hyper-
tension and regular use of amphetamines was examined using a
conditional logistic regression model that also included level of
education, cigarette smoking and regular use of analgesics. Using
BMI of< 22 as the reference category, adjusted ORs for RCC were
1.6 (95% CI = 1.2-2.0) for BMI of22-<28, 2.1 (95% CI = 1.4-3.1)
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Table 4 The relationship between use of diuretics and rsk of renal cell carcinoma
Any diuretic Thiazides Potassium-sparing diuretics
Cases Controls ORa (95% Cl) Cases Controls ORa (95% Cl) Cases Controls ORa (95% Cl)
No use of diuretics 846 1006 1.0 846 1006 1.0 846 1006 1.0
Regular useb 358 198 1.9 (1.6-2.4) 320 181 1.9 (1.5-2.4) 199 105 2.0 (1.6-2.7)
No hypertension 25 24 1.2 (0.7-2.2) 18 20 1.1 (0.6-2.1) 11 11 1.2 (0.5-3.0)
Cumulative dose CM (g)c.d
Low 11 11 1.0 (0.4-2.5) 6 9 0.8 (0.3-2.4) 5 6 0.9 (0.2-3.2)
Medium 5 5 1.6 (0.5-5.9) 3 4 1.0 (0.2-4.5) 3 3 1.7 (0.3-8.5)
High 7 8 1.0 (0.3-2.8) 6 7 1.0 (0.3-3.3) 2 2 1.1 (0.1-8.5)
Adjusted mean CM (g) 107 115 82 91 81 46
Two-sided P-valuee 0.85e 0.85e 0.29e
Hypertension 333 174 2.0(1.6-2.5) 302 161 2.0 (1.6-2.5) 188 94 2.1 (1.6-2.8)
Cumulative dose (g)c,d
Low 97 49 2.3 (1.6-3.4) 52 35 1.9 (1.2-3.0) 53 24 2.6 (1.5-4.3)
Medium 100 56 1.8(1.3-2.6) 121 61 2.0 (1.4-2.8) 58 31 2.1 (1.3-3.3)
High 106 53 2.1 (1.4-3.0) 99 48 2.2 (1.5-3.3) 57 31 1.8 (1.1-3.0)
Adjusted mean CM (g) 185 157 125 92 113 111
Two-sided P-valuee 0.32e 0.19e 0.95e
a OR, odds ratio, adjusted for level of education (high school or less, college or above) and usual body mass index (kg m-2); Cl, confidence interval.
bDefined as two or more times a week for 1 month or longer. cThe sum may be slightly less than the total number of users because of the exclusion of subjects
with missing values in cumulative dose. dCumulative dose for low, medium and high levels, respectively, were: <43, 43-136, .137 for any diuretics; <17, 17-72,
.73 for thiazides and <28, 28-100, .100 for potassium-sparing diuretics. eAnalysis of covariance with cumulative dosage of diuretics and level of education
(high school or less, college or above) as main effects, and age and usual body mass index (kg m-2) as regression covariates.
Table 5 The relationship between use of diet pills and risk of renal cell carcinoma
Cases Controls OR (95% Cl)
Regular use of any diet pillb
No 1028 1094 1.0
Yes 176 110 1.6 (1.2-2.1)
Amphetamines only 89 47 2.0 (1.3-2.9)
Non-amphetamines only 57 49 1.1 (0.7-1.7)
Combined use 30 14 2.0 (0.96-4.0)
Regular use of amphetamine-containing diet pillsb
No 1085 1143 1.0
Yes 119 61 2.0 (1.4-2.8)
Maximum weekly dose of amphetamine (mg)c
1-37.5 25 18 1.5 (0.7-2.9)
37.6-75.0 33 22 1.9 (1.04-3.4)
.75.1 55 18 2.6 (1.5-4.6)
Reason for usec
Weight reduction 68 31 2.1 (1.3-3.3)
Other 45 28 1.8 (1.1-3.0)
a OR, odds ratio, adjusted for level of education (high school or less, college or above), usual body mass
index (kg m-2), and history of hypertension; Cl, confidence interval. bDefined as two or more times a week for
1 month or longer. cThe sum may be slightly less than the total number of users due to the exclusion of
subjects with missing values in the analysis.
for BMI of 28-<30, and 3.4 (95% CI = 2.3-4.9) for BMI of.30.
The adjusted OR was 1.9 (95% CI = 1.6-2.3) for a history of
hypertension and 1.7 (95% CI = 1.2-2.5) for regular use of
amphetamines.
Analyses that excluded the 98 pairs who were not matched on
race did not materially change the associations of RCC risk with
obesity, history ofhypertension, and use ofdiuretics, antihyperten-
sives or diet pills.
Ofthe 778 prescription diuretics reported by study subjects (520
by cases, 258 by controls), physician response rate was similar
between cases (35%) and controls (40%). Brand name concor-
dance rate was 62% in cases and 62% in controls. Of the 129
physician responses with dosage information, concordance rate
was 94% in cases and 91% in controls.
Study subjects reported 873 individual non-diuretic antihyperten-
sive prescriptions (552 by cases, 321 by controls). Physician
response rate was similar between cases (39%) and controls (38%).
Brand name concordance rate was equally high among cases (67%)
and controls (63%). Of the 182 physician responses with dosage
information, concordanceratewas 88% incases and 86% in controls.
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Study subjects reported 295 individual prescription diet pills
(182 by cases, 113 by controls), but only a few of these could be
validated. Sixty-three per cent ofthese diet pills were used at least
20 years ago, so either subjects could not recollect the name of
physician who prescribed the diet pills, the named physician could
not be located or the patient's medical records could not be found.
Moreover, many patients did not get their diet pills through the
conventional healthcare system.
DISCUSSION
To our knowledge, the present study is the largest case-control
study of RCC ever conducted on a single, geographically defined
study population. Our study was specifically designed to examine
the association ofRCC with use ofdiuretics, antihypertensives and
diet pills, as well as with the conditions (hypertension and obesity)
that call for the use of these drugs. Diagnoses of all cases were
histologically confirmed; 14% clear cell carcinoma; 2% granular
cell carcinoma; and the remaining 84% renal cell carcinoma
without cell type specification. The names of all commonly used
diuretics, antihypertensives, and diet pills were explicitly listed in
the study questionnaire. In a separate section ofthe questionnaire,
a detailed medical history that included physician-diagnosed
hypertension was collected. Comparison of responses from these
two sections of the questionnaire revealed a remarkable degree of
consistency in recalled information from subjects. Moreover, RCC
patients did not differ from control subjects in the degree of
consistency between self-reported and validated information on
use of diuretics and antihypertensives, even although only a rela-
tively small percentage of medications were validated. Most
importantly, the large sample size of this study allows for the
effects ofdiuretics and antihypertensives to be investigated among
those who were prescribed these drugs for reasons other than
hypertension control, and to explore differences in risk between
treated and untreated hypertensives.
The present data do not implicate use ofdiuretics as an indepen-
dent risk factor for RCC. Since our first observation ofan associa-
tion between diuretic use and RCC (Yu et al, 1986), a number
of case-control studies have substantiated this relationship
(McLaughlin et al, 1988; Finkle et al, 1993; Kreiger et al, 1993;
Hiatt et al, 1994; Weinmann et al, 1994). These later studies,
however, all suffer from one or more ofthe major flaws present in
our earlier investigation (crude exposure assessment, inclusion of
proxy interviews, small sample size and limited analysis to sepa-
rate treatment effects from their indications). Heath et al (1997)
recently reported, from a cohort study of 1.2 million adult
Americans, that use of diuretics was associated with a 60%
increased risk of death from RCC in women but not in men.
However, this result was not adjusted for a history ofhypertension
and obesity. Recently, McLaughlin et al (1995) described a large,
multicentre study involving 1732 renal cell cancer patients and
2309 controls, which circumvented many of the design flaws of
the earlier studies. The investigators noted no association between
diuretic use and risk ofRCC afteradjustment for study centre, age,
sex, BMI, cigarette smoking and history ofhypertension.
Spironolactone, a potassium-sparing diuretic, has been found to
be tumorigenic in experimental animals (BeDell, 1996). Ron et al
(1987) reported a non-significant association with thyroid cancer
based on two positive cases and one positive control. We found no
clear evidence that the compound is a renal carcinogen.
There is no a priori reason to suspect that non-diuretic anti-
hypertensives (beta blockers, central antiadrenergic agents,
neuronal depleting agents, angiotensin-converting enzyme
inhibitors and vasodilators) are renal carcinogens. However,
McLaughlin et al (1995) recently reported that long-term use (5 or
more years) of these drugs was associated with a significant
increase in risk of RCC independent of a history ofhypertension,
although no dose-response relationship was observed with cumu-
lative dosage of any of the major classes of antihypertensives.
Heath et al (1997) showed that use ofantihypertensives was asso-
ciated with a statistically significant increase in risk ofdeath from
RCC among female participants of the American Cancer Society
Cohort Study. However, the effects of antihypertensives and
history ofhypertension could not be disentangled and no statisti-
cally significant dose-response relation between lifetime duration
of use or dosage per month and risk of RCC was observed. We
detected nopositive association between regular use ofsuch drugs
and RCC risk after adjustment for hypertension status. The fact
that similar risks ofRCC were observed between never- and ever-
treated hypertensives also argues against the non-diuretic anti-
hypertensives having substantial independent effects on RCC risk.
Several studies have reported ahigh risk ofRCC in obese indi-
viduals, especially women (Yu et al, 1986; Mellemgaard et al,
1995; Chow et al, 1996) and the present study confirms this in
both men and women.
Hypertension is clearly amajorindependent risk factor for RCC
in the present study. The association between hypertension and
RCC is unlikely to be the consequence ofrenal cancer as subjects
who were diagnosed with hypertension 20 or more years before
cancer diagnosis still experienced a statistically significant two-
fold elevation in risk. This is not a novel finding as numerous
case-control and cohort studies have also observed this relation-
ship (Raynor et al, 1981; Grove et al, 1991; Kreiger et al, 1993;
Heath et al, 1997). Diabetes and stroke, which are known to be
related to obesity and hypertension, were also associated with
RCC risk in our study, but these associations disappeared after
adjustment forobesity and history ofhypertension.
Experimental work in rodents has demonstrated thatobesity and
hypertension can lead to renal glomerulosclerosis and tubulointer-
stitial cell proliferation (Keane et al, 1993; Mai et al, 1993;
O'Donnell et al, 1993; Eng et al, 1994). As far as we know, none
of these rodent models included tumour development as an
outcome measurement, and their relevance to human renal
carcinogenesis is uncertain.
Amphetamine use was associated with increased risk ofRCC in
the present study. A dose-response relation between maximum
weekly dose and risk of RCC was observed in both men and
women. In case recall bias might explain this association, we indi-
rectly addressed this issue in anon-going study ofbladdercancerin
Los Angeles, which uses the samequestionnaireregarding medica-
tion use as the RCC study. A total of 1232 bladder cancer patients
and an equal number of age-, sex- and race-matched neighbour-
hood controls were included in this analysis. The bladder cancer
patients were slightly younger (aged 25-69 years) than the RCC
patients. The exposure profiles of amphetamines among the
controls inboth thebladdercancerstudy and thepresentstudy were
similar. There were 81 (6.6%) bladder cancer patients and 78
(6.3%) control subjects who had ever used amphetamine-
containing diet pills regularly. The relative risk of bladder cancer
for regular use of amphetamines was 0.9 (95% CI = 0.6-1.2) and
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there was no dose-response relation between maximum weekly
dose ofamphetamines and risk ofbladder cancer (P = 0.67, linear
trendtest). In arecent multicentre study, Mellemgaard et al. (1995)
also reported a statistically significant increase in risk of RCC
among amphetamine users, butwith no evidence ofincreasing risk
with increasing cumulative dose or duration of use. For a drug
such as adietpill with ausage pattern that is typically sporadic and
intermittent, self-reported duration ofuse is likely tobe inaccurate.
The role of amphetamine use in RCC aetiology requires further
investigation.
In summary, the present study has demonstrated that chronic
obesity and ahistory ofhypertension are important risk factors for
RCC in Los Angeles, California. There was no strong evidence
that use of diuretics and antihypertensives are independently
related to RCC development. Regular use of amphetamines may
be associated with an increased riskofRCC; however, the fraction
of cases possibly related to this exposure is small (population-
attributable risk = 5%).
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APPENDIX
Diuretics, aldactazide, aldactone, diuril, dyazide, enduron, esidrix,
furosemide, hydrochlorothiazide, hydrodiuril, hygroton, lasix,
metahydrin, oretic, and zaroxolyn; antihypertensives, aldomet,
apresoline, capoten, catapres, corgard, hydralazine, inderal,
lopressor, minipress, procardia, rau-sed, reserpine, serpasil and
tenormin; anddiuretic/antihypertensive combination drugs, adoril,
esimil, hydropres and serapes.
Amphetamine-containing diet pills, benzedrine, biphetamine,
dexamyl, dexedrine, eskatrol and obetrol; and non-amphetamine
containing diet pills, adipex-P, anorexin, appedrine, bacarate,
bontril PDM, control, dexatrim, didrex, fastin, ionamin, plegine,
pondimin, pre-sate, preludin, prolamine, sanorex, statobex,
tenuate, tepanil and voramil.
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